1. Home
  2. RCUS vs RAPP Comparison

RCUS vs RAPP Comparison

Compare RCUS & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCUS
  • RAPP
  • Stock Information
  • Founded
  • RCUS 2015
  • RAPP 2022
  • Country
  • RCUS United States
  • RAPP United States
  • Employees
  • RCUS N/A
  • RAPP N/A
  • Industry
  • RCUS Biotechnology: Pharmaceutical Preparations
  • RAPP
  • Sector
  • RCUS Health Care
  • RAPP
  • Exchange
  • RCUS Nasdaq
  • RAPP Nasdaq
  • Market Cap
  • RCUS 1.2B
  • RAPP 1.2B
  • IPO Year
  • RCUS 2018
  • RAPP 2024
  • Fundamental
  • Price
  • RCUS $17.35
  • RAPP $25.93
  • Analyst Decision
  • RCUS Buy
  • RAPP Strong Buy
  • Analyst Count
  • RCUS 8
  • RAPP 3
  • Target Price
  • RCUS $26.50
  • RAPP $35.33
  • AVG Volume (30 Days)
  • RCUS 1.2M
  • RAPP 441.3K
  • Earning Date
  • RCUS 11-05-2025
  • RAPP 11-07-2025
  • Dividend Yield
  • RCUS N/A
  • RAPP N/A
  • EPS Growth
  • RCUS N/A
  • RAPP N/A
  • EPS
  • RCUS N/A
  • RAPP N/A
  • Revenue
  • RCUS $262,000,000.00
  • RAPP N/A
  • Revenue This Year
  • RCUS N/A
  • RAPP N/A
  • Revenue Next Year
  • RCUS N/A
  • RAPP N/A
  • P/E Ratio
  • RCUS N/A
  • RAPP N/A
  • Revenue Growth
  • RCUS 6.07
  • RAPP N/A
  • 52 Week Low
  • RCUS $6.50
  • RAPP $6.43
  • 52 Week High
  • RCUS $18.98
  • RAPP $42.27
  • Technical
  • Relative Strength Index (RSI)
  • RCUS 64.78
  • RAPP 52.13
  • Support Level
  • RCUS $16.41
  • RAPP $24.85
  • Resistance Level
  • RCUS $18.42
  • RAPP $27.17
  • Average True Range (ATR)
  • RCUS 1.17
  • RAPP 1.46
  • MACD
  • RCUS 0.04
  • RAPP -0.37
  • Stochastic Oscillator
  • RCUS 75.30
  • RAPP 49.28

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: